SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (NYSE:KCI), a global medical technology company with leadership positions in advanced wound care and therapeutic surfaces, today announced that the U.S. Food and Drug Administration (FDA) has cleared expanded Indications for Use for KCI’s V.A.C. negative pressure wound therapy system. Specifically, the FDA has cleared KCI to market and label the unique mechanisms of action of the V.A.C. device, including “preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and removing exudate and infectious material.” The expanded Indications for Use are specific to KCI’s V.A.C. Therapy devices, which are used to treat a variety of wounds, including chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts.
